Catalog No.
KDB94002
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative competitive enzyme immunoassay technique. An antibody specific for Insulin Aspart has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled Insulin Aspart and then pipetted into the wells. Insulin Aspart in the sample competitively binds to the pre-coated antibody with biotin-labeled Insulin Aspart. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Insulin Aspart bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Insulin Aspart concentration in serum, plasma and cell culture supernates.
Detection method
Colorimetric
Sample type
Plasma, Serum, cell culture supernates
Assay type
Quantitative
Range
31.25 - 2,000 ng/mL
Sensitivity
19.08 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
1564.4
|
211.1
|
69.5
|
962.6
|
304.9
|
63.5
|
|
Standard deviation
|
183.0
|
23.1
|
10.5
|
126.6
|
42.9
|
10.5
|
|
CV (%)
|
11.7
|
11.0
|
15.1
|
13.2
|
14.1
|
16.5
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Effects of regular, glulisine, and aspart insulin on vascular endothelial growth factor and angiotensinogen expression in hyperglycemic retinal pigment epithelial (RPE) and human retinal endothelial cells (HRECs)., PMID:40510890
Effect of Semaglutide on C-peptide levels in patients with type 2 diabetes., PMID:40501244
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial., PMID:40482670
Fully Closed-Loop Improves Glycemic Control Compared with Pump with CGM in Adolescents with Type 1 Diabetes and HbA1c Above Target: A Two-Center, Randomized Crossover Study., PMID:40445776
Long-acting glucose-responsive insulin with swift onset-of-action., PMID:40348134
Subcutaneous Insulin Aspart Every 4 Hours in the Treatment of COVID-19 Patients With Mild-to-Moderate Diabetic Ketoacidosis: A Case Series., PMID:40309296
Insulin degludec/insulin aspart (IDegAsp) treatment on glycemic control and weight in patients with insulin experienced uncontrolled type 2 diabetes mellitus: A retrospective observational study., PMID:40258224
X-ray crystallographic and hydrogen deuterium exchange studies confirm alternate kinetic models for homolog insulin monomers., PMID:40257998
Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study., PMID:40236299
An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability., PMID:40211481
Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies., PMID:40176458
EXPRESS: Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus., PMID:40176332
Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trial., PMID:40129237
Prescription patterns and the cost of antihyperglycemic drugs in patients with diabetes mellitus in Iran from 2014 to 2019., PMID:40096947
Premixed insulin: Advantages, disadvantages, and future., PMID:40093285
Impact of Meal Insulin Bolus Timing and Bedtime Snacking on Continuous Glucose Monitoring-Derived Glycemic Metrics in Hospitalized Inpatients., PMID:40067436
Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus., PMID:40049655
What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups-Sharing Canadian perspectives., PMID:40013436
A comparison of ultra-rapid and rapid insulin in automated insulin delivery for type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials., PMID:39996365
Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers., PMID:39982761
Impact of setting distinct target blood glucose levels on endogenous insulin suppression and pharmacodynamics of insulin preparations., PMID:39959272
Efforts of the Pharmaceuticals and Medical Devices Agency of Japanese regulatory agency in supporting biosimilar development and disseminate information., PMID:39951116
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers., PMID:39930729
First Dimension Trap-and-Elute Combined with Second Dimension Reversed-Phase Liquid Chromatography Separation Using a Two-Dimensional-Liquid Chromatography-Tandem Mass Spectrometry System for Sensitive Quantification of Human Insulin and Six Insulin Analogs in Plasma: Improved Chromatographic Resolution and Stability Testing., PMID:39930590
BioJect: An in vitro platform to explore release dynamics of peptides in subcutaneous drug delivery., PMID:39923852
Pharmacotherapy of type 1 diabetes - part 1: yesterday., PMID:39875200
Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery., PMID:39868600
Physical compatibility of insulin aspart, lidocaine, alprostadil and vancomycin with individualised two-in-one parenteral nutrition used in the neonatal intensive care unit., PMID:39863397
Autoimmune Polyglandular Syndrome Type 3: A Case Report., PMID:39834989
Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study., PMID:39817213
Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin Aspart., PMID:39815718
Long-term blood glucose control via glucose-activated transcriptional regulation of insulin analogue in type 1 diabetes mice., PMID:39806553
Severe palmoplantar keratoderma: a cutaneous complication from sub-optimally controlled type 2 diabetes., PMID:39786791
Regular human insulins versus rapid-acting insulin analogues in children and adolescents with type 1 diabetes: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis., PMID:39763007
Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China., PMID:39703112
Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study., PMID:39691304
Pharmacological characteristics of once-weekly insulin icodec in Japanese individuals with type 1 diabetes., PMID:39665530
Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 Diabetes., PMID:39643003
Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II., PMID:39629799
Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study., PMID:39620193
A Case of Exogenous Insulin Autoimmune Syndrome: A Case Report., PMID:39575003
Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial., PMID:39546502
Survey of fear and compliance of Insulin Degludec and Insulin Aspart injection in type 2 diabetes mellitus patients and analysis of influencing factors., PMID:39533598
Sensor-derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster acting insulin aspart or insulin aspart-A secondary analysis of the CopenFast trial., PMID:39497517
Analysis of multi-disulfide bridges for insulin aspart by stepwise reduction and differentiated alkylation., PMID:39472333
Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study., PMID:39464932
Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing., PMID:39460908
Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database., PMID:39457586
For research use only. Not for human or drug use.
